Latest Retail Investors News

Electro Optic Systems (ASX:EOS) has dramatically expanded its Share Purchase Plan from $25 million to $40 million after receiving $95 million in applications, reflecting robust support from retail investors. Approximately 5 million new shares will be issued at $8.00 each, matching recent institutional pricing.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

EBR Systems has kicked off a fully underwritten 1-for-2 entitlement offer priced at $0.38 per CDI, aiming to raise $85.6 million to accelerate commercialisation and manufacturing of its wireless cardiac pacing technology.

Butn Limited has unveiled the Moneybox Retail Credit Fund, marking its strategic entry into retail private credit investing with a digital platform targeting SME loans.

Ryman Healthcare has opened a NZ$100 million fixed rate bond offer maturing in 2032, featuring an exchange mechanism for existing bondholders and a minimum interest rate of 5.60%. The offer targets institutional and retail investors and aims to refinance debt and diversify funding.

Scales Corporation has declared a final FY2025 dividend of 12.5 cents per share, lifting total dividends for the year to 25 cents, representing 59% of underlying net profit. The company also introduced a Dividend Reinvestment Plan offering shares at a 2% discount.

Nova Minerals has secured New South Wales Supreme Court approval for its schemes of arrangement, paving the way for its US holding company to take control and triggering ASX delisting and NYSE admission.

Paradigm Biopharmaceuticals has successfully raised $21.375 million through an oversubscribed Share Purchase Plan and a recent placement, bolstering its balance sheet ahead of key Phase 3 trial milestones.

Navigator Global Investments has wrapped up its $145 million entitlement offer, securing $4.1 million from retail investors despite modest participation, with the remainder allocated to sub-underwriters.

BWP Group has successfully closed its $228 million fully underwritten entitlement offer, with retail investors contributing $19 million and institutional investors covering the balance.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

Argo Global Listed Infrastructure Limited (ASX: ALI) has opened a Share Purchase Plan allowing eligible shareholders to buy up to $30,000 of new shares at a discount, aiming to boost fund size and cost efficiency.